Viva Biotech Holdings Annual Report 2025: Detailed Investor Analysis

Financial Performance Highlights

• Revenue Decline: The Group reported revenue of RMB1,729.4 million for the year ended December 31, 2025, a 12.9% decrease from RMB1,986.7 million in 2024.
• Gross Profit and Margin: Gross profit was RMB655.6 million, down 4.6%, but gross profit margin improved to 37.9% (up 3.3 percentage points), attributed to business mix optimization and operational efficiency.
• Net Profit Surge: Net profit rose sharply by 21.3% to RMB269.3 million, driven by improved profitability and successful exits from incubation portfolio companies.
• Adjusted Non-IFRS Net Profit: Adjusted net profit increased 6.6% to RMB335.3 million, reflecting the core operating performance by excluding non-cash and non-recurring items.
• Gearing Ratio: Improved to 44.4% from 45.9% in 2024, indicating enhanced financial stability.
• Earnings Per Share: Basic EPS was RMB0.10 and diluted EPS RMB0.09.
• Bank Balances and Cash: Cash reserves grew to RMB1,088.8 million, up from RMB941.6 million in 2024.

Dividend Policy and Shareholder Returns

• No Dividend Declared: The Board did not recommend a final dividend for 2025. Shareholders should note the ongoing policy of retaining earnings for growth and investment.
• Share Buyback: Viva Biotech repurchased 4,327,500 shares in 2025 for approximately HK\$5.4 million, citing undervaluation as a reason. This could be viewed as a confidence signal and may positively impact share value.
• Dividend Guidance: Board intends to distribute up to 40% of distributable profit (excluding unrealized fair value gains) in future years, subject to shareholder approval and sufficient working capital, but no guarantee of payout.

Operational Developments and Business Strategy

• Business Model: Viva Biotech operates as an investment holding company, providing structure-based drug discovery, clinical R&D, and commercialization services globally, targeting biotech and pharma customers.
• Segment Performance: Main growth drivers were CRO business and Langhua Pharmaceutical’s improved business mix. Investment income from incubation portfolio exits also contributed.
• Capital Expenditure: Capital expenditure fell to RMB85.8 million from RMB134.3 million in 2024, reflecting tighter investment focus. No new material investment plans disclosed for 2026.
• Strategic Partnerships: Group collaborated extensively with strategic investors, improving corporate governance, business operations, and financing activities.
• Material Transactions: No significant acquisitions or disposals of subsidiaries or assets exceeding 5% of total assets during the period.

Risk Factors and Shareholder Warnings

• Competitive Risks: Intensified competition from global pharmaceutical R&D service providers and emerging players with stronger resources may threaten Viva’s market share and profitability.
• Talent Retention: Losing core technicians or executives could negatively impact reputation, competitiveness, and sustained profitability. Incentive mechanisms and HR policies are crucial.
• Market Demand Uncertainty: Declines in client outsourcing demand may adversely affect revenue and growth.
• Foreign Exchange Exposure: Most revenue is USD-denominated, while expenses are RMB-denominated. Significant RMB appreciation could pressure profits. While hedging products are used, effectiveness is limited.
• Incubation Portfolio Risks: Early-stage biotech investments are speculative, with uncertain returns and fair value volatility that could materially affect earnings.
• Political and Economic Risks: Overseas revenue is substantial, and changes in laws, policies, international tensions, or force majeure events could impact demand and growth.
• Environmental and Safety Compliance: Extensive policies and procedures are in place for environmental factors, hazardous material management, and employee safety. Any lapses may expose the company to regulatory and reputational risks.

Corporate Governance and Management

• Board and Committees: Board is primary decision-making body, supported by audit, remuneration, and nomination committees. Directors are regularly trained and updated on regulatory requirements.
• Share Incentive Schemes: Several share option and restricted share unit (RSU) schemes are in place, with detailed vesting schedules and performance criteria. These schemes may affect share dilution and employee motivation.
• Major Customers: Top five customers contributed 33.8% of total revenue; largest customer accounted for 25.6%. Supplier concentration also noted, with largest supplier at 11.2% of purchases.
• Legal Proceedings: No material legal proceedings reported.

Financial Statement and Audit

• Audit Opinion: Ernst & Young provided an unqualified opinion, noting key audit matters such as fair value measurement for unlisted investments, which involve significant management estimates.
• Fair Value Hierarchy: As of December 31, 2025, RMB770.6 million of unlisted investments are valued using level 3 inputs, meaning significant unobservable assumptions—potential for volatility in earnings.
• Capital Management: The company maintains healthy capital ratios, not subject to externally imposed requirements, and adjusts its structure in response to business needs.
• Financial Risk Management: Interest rate, foreign currency, credit, and liquidity risks are actively managed, with scenario sensitivity disclosures provided.

Shareholder Rights and Communication

• EGM Convening: Shareholders holding at least 10% of voting shares can requisition extraordinary general meetings.
• Investor Communication: Company maintains open communication channels via website, email, and annual meetings. No material changes to constitutional documents during 2025.

Price-Sensitive and Share Value Impacting Information

• Revenue Decline: The significant drop in revenue, despite improved net profit, could be seen as a concern for future growth, potentially affecting share value.
• Share Buyback: The repurchase of shares at perceived undervaluation may provide support to the share price and signal management confidence.
• Risks: Exposure to currency fluctuations, competitive pressures, and uncertain returns from the incubation portfolio are material risks that could impact earnings and share value.
• No Dividend: The continued withholding of dividends may frustrate income-focused investors, but signals reinvestment in growth.
• Unlisted Investment Valuation: The substantial level-3 fair value assets may lead to earnings volatility and warrant close investor attention.

Conclusion

Viva Biotech Holdings’ 2025 Annual Report presents a mixed picture: while net profit and margins improved, revenue fell sharply. The company’s share buyback and strong cash position signal confidence, but competitive, market, and incubation portfolio risks remain. With no dividend payout and substantial exposure to unlisted investment fair value changes, investors are advised to monitor developments closely. The report contains several factors that could materially influence share price—both positively and negatively—in the coming periods.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult their own advisors and read the full annual report before making investment decisions. The author and publisher accept no liability for any losses arising from reliance on this information.

View VIVA BIOTECH Historical chart here